Literature DB >> 8984676

Mechanisms of action of interferon-beta in multiple sclerosis.

B G Arnason1, A Dayal, Z X Qu, M A Jensen, K Genç, A T Reder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8984676     DOI： 10.1007/bf00792613

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  142 in total

1.  Transcription of interferon-stimulated genes is induced by adenovirus particles but is suppressed by E1A gene products.

Authors:  N Reich; R Pine; D Levy; J E Darnell
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

2.  Inhibition of passive localized experimental allergic encephalomyelitis by interferon.

Authors:  S L Abreu; J Tondreau; S Levine; R Sowinski
Journal:  Int Arch Allergy Appl Immunol       Date:  1983

3.  Suppressor cell function in multiple sclerosis.

Authors:  B G Arnason; J Antel
Journal:  Ann Immunol (Paris)       Date:  1978 Feb-Mar

4.  Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1.

Authors:  L D Johns; K C Flanders; G E Ranges; S Sriram
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

5.  Eicosenoids Modify Experimental Allergic Encephalomyelitis.

Authors:  Anthony T. Reder; Manjula Thapar; Anna Maria Sapugay; Mark A. Jensen
Journal:  Am J Ther       Date:  1995-09       Impact factor: 2.688

6.  In situ inactivation of infiltrating T cells in the central nervous system with autoimmune encephalomyelitis. The role of astrocytes.

Authors:  Y Matsumoto; H Hanawa; M Tsuchida; T Abo
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

7.  Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist.

Authors:  E Vannier; L C Miller; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

8.  Interferon in experimental autoimmune encephalomyelitis: intraventricular administration.

Authors:  S L Abreu; I Thampoe; P Kaplan
Journal:  J Interferon Res       Date:  1986-12

9.  Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors.

Authors:  M A Collart; D Belin; J D Vassalli; S de Kossodo; P Vassalli
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

10.  Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.

Authors:  C Huber; J R Batchelor; D Fuchs; A Hausen; A Lang; D Niederwieser; G Reibnegger; P Swetly; J Troppmair; H Wachter
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307
View more
  12 in total

Review 1.  Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neurological diseases.

Authors:  George M O'Keefe; Vince T Nguyen; Etty N Benveniste
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

2.  Multiple sclerosis-linked and interferon-beta-regulated gene expression in plasmacytoid dendritic cells.

Authors:  Latt Latt Aung; Andrew Brooks; Steven A Greenberg; Michael L Rosenberg; Suhayl Dhib-Jalbut; Konstantin E Balashov
Journal:  J Neuroimmunol       Date:  2012-06-09       Impact factor: 3.478

3.  Chemotherapeutics in the treatment of multiple sclerosis.

Authors:  Bernd C Kieseier; Douglas R Jeffery
Journal:  Ther Adv Neurol Disord       Date:  2010-09       Impact factor: 6.570

4.  The influences of cytokines as a possible substrate for the psychological effects of immunomodulation therapy in multiple sclerosis.

Authors:  N N Spirin; D S Kasatkin
Journal:  Neurosci Behav Physiol       Date:  2009-01

Review 5.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 6.  The mechanism of action of interferon-β in relapsing multiple sclerosis.

Authors:  Bernd C Kieseier
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

7.  Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon β-1b.

Authors:  Lijian Yu; Ed Croze; Ken D Yamaguchi; Tiffany Tran; Anthony T Reder; Vladimir Litvak; Michael R Volkert
Journal:  J Interferon Cytokine Res       Date:  2014-10-20       Impact factor: 2.607

8.  Relationship between Neutrophil-to-Lymphocyte Ratio and Stress in Multiple Sclerosis Patients.

Authors:  Fawaz Al-Hussain; Meshal Mohammed Alfallaj; Abdulaziz Nasser Alahmari; Abdullah Nasser Almazyad; Talal Khalid Alsaeed; Abdulmjeed Abdulaziz Abdurrahman; Ghulam Murtaza; Shahid Bashir
Journal:  J Clin Diagn Res       Date:  2017-05-01

Review 9.  Long-term treatment of multiple sclerosis with interferon-beta may be cost effective.

Authors:  M Kendrick; K I Johnson
Journal:  Pharmacoeconomics       Date:  2000-07       Impact factor: 4.981

10.  Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

Authors:  A Bertolotto; A Sala; S Malucchi; F Marnetto; M Caldano; A Di Sapio; M Capobianco; F Gilli
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-09       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.